Article

VYD2311 is a promising candidate for passive immunization against COVID-19 in immunocompromised individuals

2026-04-01

Abstract excerpt

For millions of immunocompromised individuals, vaccines may not elicit adequate protection from infections, so alternative strategies for pre-exposure prophylaxis are essential. There is only one non-vaccine product authorized in the U.S. as pre-exposure prophylaxis against COVID-19: the monoclonal antibody pemivibart. We previously showed that pemivibart had lower neutralizing activity in vitro against many rece...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d7335f93-3db6-551a-a420-e2f973c857cd
DOI: 10.64898/2026.03.31.715419

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

VYD2311 is a promising candidate for passive immunization against COVID-19 in immunocompromised individualsDOI 10.64898/2026.03.31.715419Read

Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineagesSemantic proximity Read

Immunobridging Analysis of Pemivibart for the Treatment of COVID-19 – A Therapeutic Gap for the Immune Compromised RemainsSemantic proximity Read

Structural and functional analysis of VYD222: a broadly neutralizing antibody against SARS-CoV-2 variantsSemantic proximity Read

Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineageSemantic proximity Read

Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics.Semantic proximity Read

Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients.Semantic proximity Read

Broad-Spectrum Heavily Mutated Monoclonal Antibody Isolated from COVID-19 Convalescent Vaccinee with Capacity to Neutralize SARS-CoV2 Variants Ranging from B.1 to BQ.1.1Semantic proximity Read

Long-term passaging of replication competent pseudo-typed SARS-CoV-2 reveals the antiviral breadth of monoclonal and bispecific antibody cocktailsSemantic proximity Read

Preclinial Safety and Efficacy of a Therapeutic Antibody That Targets SARS-CoV-2 at the Sotrovimab Face But is Escaped by OmicronSemantic proximity Read

An Overview of the Immune Response to COVID-19 Vaccination and Strategies to Boost SARS-CoV-2 Immunity in People with Inborn Errors of ImmunitySemantic proximity Read

A single intramuscular injection of monoclonal antibody MAD0004J08 induces in healthy adults SARS-CoV-2 neutralising antibody titres exceeding those induced by infection and vaccinationSemantic proximity Read

Escape of SARS-CoV-2 variants KP1.1, LB.1 and KP3.3 from approved monoclonal antibodiesSemantic proximity Read